Skip to main content

Table 3 Multivariate Analyses of Survival in the First Study Population (N = 774)

From: Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients

Variable DRFS DSS
HR 95% CI P HR 95% CI P
Age       
  ≤ 50 yr. vs. > 50 yr 0.84 0.56–1.26 0.40 0.63 0.36–1.10 0.10
ER status       
 Negative vs. Positive 1.93 0.98–3.79 0.06 1.51 0.62–3.72 0.37
PR status       
 Negative vs. Positive 1.32 0.77–2.25 0.31 2.13 1.09–4.15 0.027
HER2 status       
 Positive vs. Negative 0.88 0.56–1.39 0.59 0.75 0.42–1.36 0.34
Tumor grade       
 III vs. I/II 1.18 0.70–1.99 0.53 1.47 0.77–2.80 0.24
Tumor size       
  > 2 cm vs. ≤2 cm 1.52 0.97–2.38 0.07 2.26 1.17–4.40 0.017
Adjuvant chemotherapy       
 C vs. no therapy 0.91 0.42–1.97 0.81 1.63 0.55–4.85 0.38
 E vs. no therapy 1.14 0.47–2.80 0.77 1.71 0.47–6.25 0.42
 C + E vs. no therapy 1.63 0.69–3.85 0.26 2.00 0.56–7.16 0.29
Lymph node status       
 Positive vs. Negative 3.56 2.35–5.38 < 0.001 4.09 2.35–7.10 < 0.001
RECQL mRNA expression       
 Low vs. High 3.04 1.89–4.87 < 0.001 4.25 2.12–8.46 < 0.001
  1. Abbreviations: DRFS, distant recurrence-free survival; DSS, disease-specific survival; HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2;C,chemotherapy; E, endocrinotherapy; C + E, chemotherapy and endocrinotherapy